In the case of the medulloblastoma, BRCA1 mutations may be targeted with DNA damaging drugs such as platinum and PARP inhibitors that are currently in clinical trials for brain tumors[7-9]; furthermore, the PTCH-1 aberration seen in medulloblastoma could be targeted with SMO/SHH inhibitors such as vismodegib[10]. This evidence concerns the gene SMO and brain neoplasm.